Neural correlates of the LSD experience revealed by multimodal neuroimaging

By Robin L. Carhart-Harris, Suresh D. Muthukumaraswamy, Leor Roseman, M. Kaelen, Wouter Droog, Kevin Murphy, Enzo Tagliazucchi, E. Schenberg, T. Nest, C. Orban and 16 more. Proceedings of the National Academy of Sciences of the United States of America, 2016

759 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Clinical Psychology, Nutrition and Dietetics

View Paper: https://www.semanticscholar.org/paper/58596905300a765934307e43479e6d8493f88cf8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. Karl J. Friston
2. Robin L. Carhart-Harris
3. David J. Nutt
4. Leor Roseman

In Clinical Psychology

1. Robin L. Carhart-Harris
2. Karl J. Friston
3. David J. Nutt
4. Leor Roseman
5. Guy M. Goodwin

In Nutrition and Dietetics

1. David J. Nutt
2. Robin L. Carhart-Harris

Citations in the corpus

• Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression (2018, methodology): “The development of subjective (Nour et al., 2016), behavioral and biological measures (Carhart-Harris et al., 2012, 2016b; Lebedev et al., 2015; Tagliazucchi et al., 2016) relevant to these constructs, and more importantly, the processes that underlie them, would represent an important advance not…”
• The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future (2017, background): “…clinical development of psychedelics, RLC-H sees it as a potentially exploitable component—especially as it has been shown to be predictive of long-term clinical outcomes (eg, in Johnson et al, 2014; Bogenschutz et al, 2015; Griffiths et al, 2016; Ross et al, 2016; Carhart-Harris et al, 2016a,b).”
• REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics (2019, background): “It has previously been suggested and demonstrated (Gouzoulis et al., 1994; Carhart-Harris et al., 2016b) that the acute psychedelic experience is a much better model of the early (and perhaps acute) symptoms of an incipient psychosis than symptoms associated with chronic schizophrenia, presumably…”
• Serotonin and brain function: a tale of two receptors (2017, methodology): “SSRIs are established evidence-based treatments for anxiety and major depression (Baldwin et al., 2016; Hieronymus et al., 2016), whereas psychedelics are experimental medicines in an early phase of development (Carhart-Harris and Goodwin, 2017; Carhart-Harris et al., 2016).”